37.5% of class 3 obesity entrants exited clinical obesity entirely Waist circumference reduction: -24.1 cm at 12 mg vs -3.6 cm placebo 104 wk extension (n=532, BMI 35 baseline 121.7 kg, BMI 42.8): 12 mg to MTD: -30.3% (-85.0 lbs) 9 mg to MTD: -29.5% (-80.7 lbs) 4 mg to MTD: -27.9% (-73.3 lbs) Placebo to MTD: -19.2% (-49.9 lbs) Cardiometabolic improvements vs placebo: waist circumference, non-HDL cholesterol, triglycerides, systolic BP, hsCRP 4 mg dose: AE-driven discontinuation rate lower than placebo Strategic takeaways: First triple agonist past phase 3, ahead of every competing program TWL distribution closes gap with bariatric surgery (Roux-en-Y ~30%, sleeve ~25%) Pressure on bariatric procedure volumes, PBM utilization management regimes, ICER cost-effectiveness models LLY widens lead over NVO further
Adele lost her weight mainly by working out 3 times per day
At MVP Mens Clinic in Madison, MS, patients receive personalized guidance to determine which medication is the best match for their goals and how to adjust treatment safely if progress slows
Someone managing other medications that affect digestive function may require a more tailored schedule
Specifikationer Specifikationer Genom att klicka p Skicka bekrftar du att du kan bli kontaktad av Fisher Scientific angende feedbacken du har lmnat i detta formulr
